%PDF-1.7
%
1 0 obj
<70 years\) with advanced colorectal can- cer after failure of oxaliplatin based chemothera- py twenty-three patients were evaluated. Iri- notecan 350 mg + raltitrexed 2.6 mg were given every 3 weeks. Tumo r measurements were ob- tained after every third course of therapy. Toxic- ity was assessed weekly using the National Cancer Institute Common Toxicity Criteria, ver- sion 2. Results: The median number of treatment courses received per patient was 4 \(range, 1 - 8\). All pa-tients were assessable for toxicity and 21 for response. The most frequently observed severetoxicities were diarrhea \(grade 2, 13%\) No cases of significant neutropenia occurred. Ob- jective partial responses were observed in 3 pa- tients \(13%\). An additional 10 patients \(43%\) had stable disease as their best response. To date, 12 patients have progressed with a median time- to-progression of 4.3 months and a median sur- vival of 8.3 months. Conclusions: A three weekly irinotecan + raltitrexed administration can indu- ce tumor control in elderly patients with advanc- ed colorectalcancer that has progressed during or shortly after oxaliplatin-based chemotherapy. The diarrhea by irinotecan, seems mitigated by coad-ministration of a smaller dose of raltitrexed)/SourceModified(D:20131202062448)/_EmailSubject(proof)/Creator(Scientific Research Publishing)/Title(Raltitrexed + irinotecan as second-line chemotherapy in elderly patients with advanced colorectal cancer)/Comments()/_AuthorEmail(kcchou@gordonlifescience.org)/MTWinEqns(1)/CreationDate(D:20131202142513+08'00')/Author(Barbara Vandendriessche, Filip Geurs, Ingeborg Hilderson)/_PreviousAdHocReviewCycleID(2069326740)>>
endobj
2 0 obj
<>stream
endstream
endobj
3 0 obj
<>/ProcSet[/PDF/Text]/ColorSpace<>/Font<>/Properties<>>>/MediaBox[0 0 595 808]/StructParents 4/Rotate 0>>
endobj
5 0 obj
<>stream
HWr}WL,Vٞ[̸J0Jd&4%!{9
IJU".}tcyzWm嵵l;?7775